Revenues

Revenues by product and by geographic area

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold principally in Europe. Revenues were as follows (in millions):



	Three months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	1,242	$	50	$	1,292	$	1,309	$	54	$	1,363
Neulasta^®	897		154		1,051		977		146		1,123
Prolia^®	354		178		532		298		166		464
Aranesp^®	248		229		477		285		231		516
XGEVA®	323		110		433		282		105		387
Sensipar^® / Mimpara^®	330		79		409		373		84		457
EPOGEN^®	252		—		252		264		—		264
Other products	614		450		1,064		509		370		879
Total product sales⁽¹⁾	$	4,260	$	1,250	$	5,510	$	4,297	$	1,156	$	5,453
Other revenues					394						320
Total revenues⁽²⁾					$	5,904					$	5,773



	Nine months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	3,544	$	155	$	3,699	$	3,838	$	172	$	4,010
Neulasta^®	2,854		452		3,306		2,962		458		3,420
Prolia^®	1,070		566		1,636		903		491		1,394
Aranesp^®	714		689		1,403		851		711		1,562
XGEVA®	994		336		1,330		872		312		1,184
Sensipar^® / Mimpara^®	1,069		257		1,326		1,052		253		1,305
EPOGEN^®	746		—		746		826		—		826
Other products	1,783		1,303		3,086		1,474		1,051		2,525
Total product sales⁽¹⁾	$	12,774	$	3,758	$	16,532	$	12,778	$	3,448	$	16,226
Other revenues					985						821
Total revenues⁽²⁾					$	17,517					$	17,047

^____________


⁽¹⁾	Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.


⁽²⁾	Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

Financing and payment

Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.

Optional exemptions

We do not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for the services performed.